After many decades of little or no progress in treating the dementia associated with Alzheimer's, a new drug now offers hope to patients and caregivers. Lecanemab, announced late last month, was found in clinical trials to slow cognitive decline in early-stage Alzheimer's patients. "It's an extremely encouraging result," says Dr. David Wolk, co-director of the University of Pennsylvania's Penn Memory Center.
The arrival of lecanemab comes with some big caveats, however. The drug has significant health risks, including bleeding and brain swelling. It's expensive drug manufacturer Esai estimates the annual price of treatment would be somewhere between $9,249 and $35,605, and it's unclear what insurance will cover. And the drug has only a modest effect on the debilitating progress of Alzheimer's.
Some scientists are also having second thoughts about the strategy that led to lecanemab-namely, trying to slow Alzheimer's solely by inhibiting the buildup of beta-amyloid, a protein that accumulates in the brain cells to form plaques. After three decades of chasing one failed treatment after another and burning through billions of dollars in research funding, lecanemab is the first unequivocally successful plaque-inhibiting treatment for Alzheimer's. (A similar drug, Aduhelm, was approved last year by the U.S. Food and Drug Administration to some controversy.) Many scientists now think amyloid plaque is only one of many factors in causing the disease's debilitating effects and call for new approaches.
The FDA is expected to decide on an accelerated approval status for lecanemab on January 6, which would enroll additional patients in new trials. If those are successful, full approval would likely arrive late next year.
Denne historien er fra December 30, 2022-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra December 30, 2022-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Wendi McLendon-Covey
AFTER 10 YEARS OF PLAYING BEVERLY GOLDBERG ON THE GOLDBERGS, Wendi McLendon-Covey was not eager for a break. \"I need to go do a job where I can just throw everything at it and then come home totally exhausted.\"
'I'm the Highest Earner in Esports'
Johan \"NOtail\" Sundstein has won over $7 million but says, \"I don't really crave that status.... I play for my own reasons\"
AMERICA'S BEST Weight Loss CLINICS & CENTERS 2025
WHETHER IT'S FOR MEAL PLANS, PROFESSIONAL guidance or access to medications like GLP-1s, weight loss clinics can offer personalized assistance for those hoping to make sustainable lifestyle changes.
AMERICA'S MOST ANTICIPATED NEW VEHICAL 2025
WHETHER IT'S A NEWLY IMAGined sport utility vehicle or the re-emergence of a highly regarded halo car, the vehicles coming to market in 2025 prove that Americans' attitudes about personal transportation are diverse and are being served from all angles.
'THIS IS WHAT DEMOCRACY LOOKS LIKE'
What Donald Trump's historic U.S. presidential election victory means to America - and the world
Trump Won, Mainstream Media Lost
A broken business model exacerbated by a collapse in influence has the Fourth Estate entering another Donald Trump term in trouble
Can Alternative Therapies Treat Cancer?
Doctor and breast cancer survivor Liz O'Riordan addresses misinformation around managing the disease
Falling for Romance
A new book, Nora Ephron at the Movies, celebrates the writer/director best known for her iconic rom-coms and strong female characters
Cracking the Norse Code
Walrus DNA has shown that Vikings were likely the first to have encountered Indigenous North Americans
Monumental Shift
The discovery of 165-million-year-old crystals Easter Island has upended the longheld notion of how the Earth's \"conveyor belt\" moves